Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Hong Kong Stock Exchange  >  Luye Pharma Group Ltd.    2186   BMG570071099

LUYE PHARMA GROUP LTD.

(2186)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Hong Kong Stock Exchange
10/23/2020 10/27/2020 10/28/2020 10/29/2020 10/30/2020 Date
4.77 4.66 4.51 4.62 4.48 Last
10910500 8013096 16314000 9842439 10952820 Volume
-1.04% -2.31% -3.22% +2.44% -3.03% Change
Financials
Sales 2020 6 673 M 997 M 997 M
Net income 2020 1 466 M 219 M 219 M
Net Debt 2020 2 163 M 323 M 323 M
P/E ratio 2020 9,61x
Yield 2020 1,63%
Sales 2021 7 182 M 1 073 M 1 073 M
Net income 2021 1 625 M 243 M 243 M
Net Debt 2021 1 112 M 166 M 166 M
P/E ratio 2021 8,83x
Yield 2021 1,76%
Capitalization 14 555 M 1 877 M 2 175 M
EV / Sales 2020 2,51x
EV / Sales 2021 2,18x
Nbr of Employees 4 822
Free-Float 53,3%
More Financials
Company
Luye Pharma Group Ltd. is an investment holding company principally engaged in the development, production, marketing and sale of pharmaceutical products. Along with subsidiaries, the Company operates its business through four segments: the Oncology Drugs segment, the Cardiovascular System Drugs segment, the Alimentary Tract and Metabolism Drugs segment and the Others segment. The Company‚Äôs main products include... 
Sector
Pharmaceuticals
Calendar
03/31Earnings Release
More about the company
Notations Surperformance© of Luye Pharma Group Ltd.
Trading Rating : Investor Rating :
More Ratings
All news about LUYE PHARMA GROUP LTD.
08/27LUYE PHARMA : Voluntary announcement - approval for clinical trial for lpm487010..
PU
08/26LUYE PHARMA : Voluntary announcement - approval for clinical trial for lurbinect..
PU
03/27LUYE PHARMA : Continues to Deliver Strong Growth in 2019
PR
03/09LUYE PHARMA : Voluntary announcement - clinical trial application of ly03014 was..
PU
03/04LUYE PHARMA : Voluntary announcement - u.s. fda accepted ly03005 nda filing
PU
02/17LUYE PHARMA : Completion of discloseable and connected transaction in relation t..
PU
02/11LUYE PHARMA : Novel approach from Synergy Pharmaceuticals may hold cure to herpe..
AQ
02/09LUYE PHARMA : Voluntary announcement - luye granted cipla medpro the exclusive d..
PU
02/04LUYE PHARMA : Voluntary announcement - proposed repurchase of shares
PU
01/31LUYE PHARMA : Voluntary announcement - luye pharma received a complete response ..
PU
2019LUYE PHARMA : Voluntary announcement - cde granted priority review status to new..
PU
2019LUYE PHARMA : Voluntary announcement - submission of nda for ly03005 to the u.s...
PU
2019LUYE PHARMA : Voluntary announcement - ansofaxine hydrochloride extended release..
PU
2019LUYE PHARMA : Voluntary announcement - triptorelin acetate extended-release micr..
PU
2019LUYE PHARMA : Discloseable and connected transaction in relation to the acquisit..
PU
More news
News in other languages on LUYE PHARMA GROUP LTD.
2018LUYE PHARMA GROUP LTD : Veröffentlichung des Jahresergebnisses
2018LUYE PHARMA GROUP LTD : publication des résultats annuels
2017Dietmar Hopp se prépare à vendre les patches LTS-sources
More news
Stock Trading Strategies
LUYE PHARMA GROUP LTD. - 04/17
A good timing to anticipate a change in the trend
BUY
More Stock Trading Analysis
Chart LUYE PHARMA GROUP LTD.
Duration : Period :
Luye Pharma Group Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends LUYE PHARMA GROUP LTD.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 12
Average target price 4,97 CNY
Last Close Price 4,48 CNY
Spread / Highest target 74,4%
Spread / Average Target 10,8%
Spread / Lowest Target -27,4%
EPS Revisions
Managers
NameTitle
Dian Bo Liu Executive Chairman & Chief Executive Officer
Rong Bing Yang Vice Executive Chairman & President
Yuan Chong Liu Chief Financial Officer
You Xin Li Vice President, Head-Research & Development
Hui Xian Yuan Executive Director & Founding Member
Sector and Competitors